Autophagy

Ana Maria Cuervo, M.D., Ph.D., Elected to the National Academy of Sciences

Retrieved on: 
Wednesday, May 1, 2019
Branches of biology, Biology, Ana Maria Cuervo, Programmed cell death, Autophagy

BRONX, N.Y., May 1, 2019 /PRNewswire/ -- Ana Maria Cuervo, M.D., Ph.D. , cell biologist and internationally recognized expert on the cellular process autophagy, has been elected to the National Academy of Sciences (NAS).

Key Points: 
  • BRONX, N.Y., May 1, 2019 /PRNewswire/ -- Ana Maria Cuervo, M.D., Ph.D. , cell biologist and internationally recognized expert on the cellular process autophagy, has been elected to the National Academy of Sciences (NAS).
  • Forty percent of the newly elected members are women, which the academy noted is the most ever elected in any one year.
  • "She is a wonderfully respected and beloved member of our community and we are all delighted.
  • For more information, please visit www.einstein.yu.edu , read our blog , followus on Twitter , like us on Facebook , and view us on YouTube .

Casma Therapeutics Establishes Scientific Advisory Board with Appointments of Leading Autophagy and Neuroscience Researchers

Retrieved on: 
Tuesday, March 26, 2019
Health, Biotechnology, Pharmaceutical, Research, Science, Programmed cell death, Cellular processes, Immunology, Autophagy

Casma Therapeutics, Inc. , a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced the appointments of Sascha Martens, Ph.D., and Pietro De Camilli, M.D., as the first members of Casmas scientific advisory board.

Key Points: 
  • Casma Therapeutics, Inc. , a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced the appointments of Sascha Martens, Ph.D., and Pietro De Camilli, M.D., as the first members of Casmas scientific advisory board.
  • I am excited to establish a scientific advisory board to help guide us as we pioneer a new class of therapies to stop or reverse disease progression, said Leon Murphy, Ph.D., chief scientific officer of Casma Therapeutics.
  • I look forward to advising the Casma team as they apply our advances to treat disorders with high unmet need.
  • Casma Therapeutics is harnessing the natural cellular process of autophagy to open vast new target areas for drug discovery and development.

Rocket Pharmaceuticals Announces Publication of Comprehensive Review of Danon Disease Cases in the International Journal of Cardiology

Retrieved on: 
Tuesday, February 26, 2019
Health, Biotechnology, Cardiology, Clinical trials, Genetics, Pharmaceutical, Research, Science, Branches of biology, Medicine, Medical specialties, Rare diseases, Danon disease, Autophagy, MTOR, Biopsy

The manuscript entitled, Danon Disease: Gender Differences in Presentation and Outcomes outlines a comprehensive review of 83 published manuscripts describing cases of Danon disease, the target indication for RP-A501.

Key Points: 
  • The manuscript entitled, Danon Disease: Gender Differences in Presentation and Outcomes outlines a comprehensive review of 83 published manuscripts describing cases of Danon disease, the target indication for RP-A501.
  • The review consisted of 90 male patients and 56 female patients for a total of 146 patients with positive genetic testing for Danon disease or positive muscle biopsy.
  • Danon disease is caused by mutations in the gene encoding lysosome-associated membrane protein 2 (LAMP-2), an important mediator of autophagy.
  • Rocket is also developing an AAV-based gene therapy program for a devastating, pediatric heart failure indication, Danon disease.

Petra Pharma Presents Preclinical PIP4K2 Inhibitor Data as a Potential Treatment for Hematologic Malignancies at the 2018 American Society of Hematology Annual Meeting

Retrieved on: 
Saturday, December 1, 2018
Medicine, Autophagy, Immunology, Programmed cell death, Tumors of the hematopoietic and lymphoid tissues, Biology, Health, Phosphoinositide 3-kinase inhibitor

NEW YORK, Dec. 1, 2018 /PRNewswire/ -- Petra Pharma Corporation , a drug development company focused on novel therapies that modulate phosphoinositide (PI) signaling pathways, today presented preclinical data in an oral presentation at the American Society of Hematology (ASH) 2018 Annual Meeting.

Key Points: 
  • NEW YORK, Dec. 1, 2018 /PRNewswire/ -- Petra Pharma Corporation , a drug development company focused on novel therapies that modulate phosphoinositide (PI) signaling pathways, today presented preclinical data in an oral presentation at the American Society of Hematology (ASH) 2018 Annual Meeting.
  • The data presented show that potent and selective inhibitors of PIP4K2 are effective at inhibiting growth of a variety of hematologic cancers including leukemia- and lymphoma-derived lines.
  • Recent evidence indicates autophagy a process that delivers cellular components to lysosomes for degradation promotes tumorigenesis and tumor cell survival in solid tumors and hematologic malignancies.
  • Lewis Cantley, Ph.D., Scientific Co-Founder of Petra Pharma, added, "Paired with current understanding of PIP4K2, our data suggest the PIP4K2 family of enzymes could serve as the foundation for potential treatments of hematologic malignancies."

Bio-Techne Leads the Way in Scientific Support for Autophagy Research

Retrieved on: 
Thursday, April 26, 2018
Biology, Cell biology, Programmed cell death, Cellular processes, Autophagy, Immunology, Lysosome, David C. Rubinsztein

MINNEAPOLIS, April 26, 2018 /PRNewswire/ --Bio-Techne, a family of brands providing a unique portfolio of products and services for basic and clinical research, has a leading role supporting autophagy research.

Key Points: 
  • MINNEAPOLIS, April 26, 2018 /PRNewswire/ --Bio-Techne, a family of brands providing a unique portfolio of products and services for basic and clinical research, has a leading role supporting autophagy research.
  • Autophagy (or "self-eating") is an important basic cellular process by which cell components are degraded by lysosomes or vacuoles and recycled.
  • Bio-Techne is deeply committed tosupporting autophagy research and forums that allow for the presentation of innovative research and the exchange of ideas focused on new developments in the field of autophagy.
  • In addition to Bio-Techne's support at this year's Gordon Research Conference: Autophagy in Stress, Development and Disease, other sponsored autophagy meetings from Q1 of FY2018 include:
    Keystone Symposia - Selective Autophagy, Kyoto, Japan
    EMBO Conference - Autophagy: From Molecular Principles to Human Diseases, Dubrovnik, Croatia
    Autophagy UK - 4th UK Autophagy Network Meeting, Cambridge, UK
    CFATG - 7th Autophagy Scientific Days, Paris, France
    Bio-Techne showcased the improved potency of Tat-D11 over Tat-Beclin1 peptides for the induction of autophagy at this year's Gordon Research Seminar: Autophagy in Stress, Development and Disease in Lucca, Italy.